このページの翻訳は実験的なもので、現在開発中です。お待ちしております

NeuroMetrix マネジメント

マネジメント基準チェック /24

NeuroMetrix'sの CEO はShai Gozaniで、 Jun1996年に任命され、の在任期間は 27.67年です。の年間総報酬は$ 645.32Kで、 64.3%給与と35.7%のボーナス（会社の株式とオプションを含む）で構成されています。は、会社の株式の0.81%を直接所有しており、その価値は€ 27.66K 。経営陣と取締役会の平均在任期間はそれぞれ10.5年と12.9年です。

主要情報

Shai Gozani

最高経営責任者

US$645.3k

報酬総額

CEO給与比率	64.3%
CEO在任期間	27.7yrs
CEOの所有権	0.8%
経営陣の平均在職期間	10.5yrs
取締役会の平均在任期間	12.9yrs

経営陣の近況

Recent updates

CEO報酬分析

NeuroMetrix の収益と比較して、Shai Gozani の報酬はどのように変化したか？
日付	総報酬	給与	会社業績
Sep 30 2023	n/a	n/a	-US$6m
Jun 30 2023	n/a	n/a	-US$5m
Mar 31 2023	n/a	n/a	-US$5m
Dec 31 2022	US$645k	US$415k	-US$4m
Sep 30 2022	n/a	n/a	-US$5m
Jun 30 2022	n/a	n/a	-US$4m
Mar 31 2022	n/a	n/a	-US$3m
Dec 31 2021	US$558k	US$415k	-US$2m
Sep 30 2021	n/a	n/a	-US$2m
Jun 30 2021	n/a	n/a	-US$1m
Mar 31 2021	n/a	n/a	-US$1m
Dec 31 2020	US$181k	US$181k	-US$2m
Sep 30 2020	n/a	n/a	-US$3m
Jun 30 2020	n/a	n/a	-US$4m
Mar 31 2020	n/a	n/a	-US$6m
Dec 31 2019	US$775k	US$422k	-US$4m
Sep 30 2019	n/a	n/a	-US$6m
Jun 30 2019	n/a	n/a	-US$3m
Mar 31 2019	n/a	n/a	US$908k
Dec 31 2018	US$478k	US$415k	US$24k
Sep 30 2018	n/a	n/a	-US$54k
Jun 30 2018	n/a	n/a	-US$7m
Mar 31 2018	n/a	n/a	-US$11m
Dec 31 2017	US$610k	US$415k	-US$20m

報酬と市場: Shaiの総報酬 ($USD 645.32K ) は、 German市場 ($USD 406.04K ) の同規模の企業の平均を上回っています。

報酬と収益: Shaiの報酬は増加しましたが、会社は利益を上げていません。

CEO（最高経営責任者

Shai Gozani (58 yo)

27.7yrs

在職期間

US$645,324

報酬

Dr. Shai N. Gozani, M.D., Ph D., founded Neurometrix Inc. in 1996 and has been its President since 2002 and Chief Executive Officer since 1997 and its Secretary July 2008. He has been the Chairman of the B...

リーダーシップ・チーム

名称	ポジション	在職期間	報酬	所有権
Shai Gozani	Founder	27.7yrs	US$645.32k	0.81% $ 27.7k
Thomas Higgins	Senior VP	14.4yrs	US$505.37k	0.63% $ 21.5k
Xuan Kong	Chief Data Scientist	6.7yrs	データなし	データなし
Susan Bell	Senior Vice President of Population Health & Value Based Care	2.3yrs	データなし	データなし

10.5yrs

平均在職期間

経験豊富な経営陣: NLZ0の経営陣は経験豊富で経験豊富です（平均在職期間は10.5年）。

取締役

名称	ポジション	在職期間	報酬	所有権
Shai Gozani	Founder	27.7yrs	US$645.32k	0.81% $ 27.7k
Nancy Katz	Independent Director	13.2yrs	US$102.86k	0.21% $ 7.0k
David Goodman	Independent Director	19.7yrs	US$107.86k	0.21% $ 7.0k
Arthur Vinik	Member of Scientific Advisory Board	12.9yrs	データなし	データなし
Andrew Boulton	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
David Van Avermaete	Independent Director	10.4yrs	US$102.86k	0.21% $ 7.0k
Neil Brooks	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
David Armstrong	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
Solomon Tesfaye	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
Dan Ziegler	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
Bruce Perkins	Member of the Scientific Advisory Board	12.9yrs	データなし	データなし
Jiro Nakamura	Member of Scientific Advisory Board	10.1yrs	データなし	データなし

12.9yrs

平均在職期間

65.5yo

平均年齢

経験豊富なボード: NLZ0の取締役会は経験豊富で経験豊富です ( 12.9年の平均在任期間)。

NeuroMetrix マネジメント

マネジメント 基準チェック /24

主要情報

経営陣の近況

Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

Insufficient new directors

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

Insufficient new directors

Recent updates

NeuroMetrix, Inc. to Report Q2, 2024 Results on Aug 06, 2024

Neurometrix, Inc. Appoints Joshua S. Horowitz as a Class III director on the Board

NeuroMetrix, Inc., Annual General Meeting, Apr 30, 2024

NeuroMetrix, Inc. Announces Publication of Study Demonstrating That DPNCheck Accurately Diagnoses Diabetic Peripheral Neuropathy

RS Fund Discloses its Views on NeuroMetrix

NeuroMetrix, Inc. to Report Q4, 2023 Results on Feb 22, 2024

NeuroMetrix, Inc. Announces Peer-Reviewed Publication of Phase 2 Clinical Trial Showing that Quell Improves Painful Symptoms of Chemotherapy Induced Peripheral Neuropathy

Third quarter 2023 earnings released: US$0.21 loss per share (vs US$0.23 loss in 3Q 2022)

NeuroMetrix, Inc. to Report Q3, 2023 Results on Oct 26, 2023

NeuroMetrix Receives Non-Compliance Notice From Nasdaq

New major risk - Revenue and earnings growth

Second quarter 2023 earnings released: US$0.20 loss per share (vs US$0.17 loss in 2Q 2022)

NeuroMetrix, Inc. to Report Q2, 2023 Results on Jul 27, 2023

NeuroMetrix, Inc. Announces Sales Force Expansion for Quell Fibromyalgia

NeuroMetrix, Inc. Announces Presentation of New Clinical Data At the Diabetes UK Meeting

NeuroMetrix, Inc. Demonstrates Encouraging Clinical Trial Results in Chemotherapy Induced Peripheral Neuropathy

First quarter 2023 earnings released: US$0.20 loss per share (vs US$0.14 loss in 1Q 2022)

Full year 2022 earnings released: US$0.62 loss per share (vs US$0.45 loss in FY 2021)

NeuroMetrix, Inc. to Report Q4, 2022 Results on Feb 23, 2023

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

NeuroMetrix, Inc. Announces Launch of DPNCheck 2.0, Its Fast, Accurate, Quantitative Screening Test for Peripheral Neuropathy

Insufficient new directors

NeuroMetrix, Inc. to Introduce Quell Fibromyalgia At the American College of Rheumatology 2022 Annual Meeting

NeuroMetrix, Inc. Announces Strategic Launch of Quell Fibromyalgia

Third quarter 2022 earnings released: US$0.23 loss per share (vs US$0.12 loss in 3Q 2021)

NeuroMetrix, Inc. to Report Q3, 2022 Results on Oct 20, 2022

Neurometrix, Inc. Appoints Jonathan Breck Harmel as National Director of Sales

Second quarter 2022 earnings released: US$0.17 loss per share (vs US$0.13 loss in 2Q 2021)

NeuroMetrix, Inc. to Report Q2, 2022 Results on Jul 21, 2022

NeuroMetrix, Inc. Appoints Brad Fluegel to Its Board of Directors, Effective July 1, 2022

NeuroMetrix, Inc. Reports Quell(R) Wearable Neuromodulation Device Received FDA De Novo Authorization as First Non-Pharmacological Treatment for Fibromyalgia

First quarter 2022 earnings released: US$0.14 loss per share (vs US$0.016 loss in 1Q 2021)

Insufficient new directors

NeuroMetrix, Inc. to Report Q1, 2022 Results on Apr 26, 2022

NeuroMetrix, Inc. Reports That Quell® Wearable Neuromodulator to Be Evaluated in Post-Acute Covid-19 Syndrome

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

NeuroMetrix Receives FDA Breakthrough Device Designation for Treatment of Chronic Chemotherapy Induced Peripheral Neuropathy (CIPN) with its Wearable Neurostimulation Technology

Third quarter 2021 earnings released: US$0.14 loss per share (vs US$0.068 loss in 3Q 2020)

Senior VP recently sold €449k worth of stock

Senior VP recently sold €231k worth of stock

Second quarter 2021 earnings released: US$0.13 loss per share (vs US$0.28 loss in 2Q 2020)

NeuroMetrix, Inc. Announces Quell Technology

NeuroMetrix Announces Top-Line Results from a Randomized Controlled Trial of Quell for Treatment of Fibromyalgia to be Presented at Two Upcoming Pain Medicine Conferences

First quarter 2021 earnings released: US$0.016 loss per share (vs US$0.45 loss in 1Q 2020)

NeuroMetrix, Inc., Annual General Meeting, Apr 27, 2021

New 90-day high: €4.12

Full year 2020 earnings released: US$0.55 loss per share (vs US$3.90 loss in FY 2019)

NeuroMetrix, Inc. to Report Q4, 2020 Results on Jan 28, 2021

New 90-day high: €3.18

New 90-day high: €2.96

New 90-day high: €1.63

New 90-day low: €1.23

Third quarter earnings released

NeuroMetrix, Inc. to Report Q3, 2020 Results on Oct 22, 2020

NeuroMetrix, Inc. Launches Quell® App for Apple Watch®, the First Smartwatch App for an Over-The-Counter Pain Relief Device

New 90-day low - €1.47

NeuroMetrix, Inc. to Report Q2, 2020 Results on Jul 23, 2020

CEO報酬分析

CEO（最高経営責任者

在職期間

報酬

リーダーシップ・チーム

平均在職期間

取締役

平均在職期間

平均年齢

マネジメント基準チェック /24